Bellicum Pharma (BLCM) Selected for Inclusion in NASDAQ Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St futures tick up as investors weigh earnings; PayPal jumps
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise 1% as hostilities worsen in the Middle East
- ASML capacity upgrade soothes AI chip bottleneck fears
- Dollar steadies as Middle East escalation counters soft US inflation
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Bellicum to be Added to the NASDAQ Biotechnology Index
December 14, 2015 4:09 PM ESTHOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index® (Nasdaq: NBI). This addition will be effective prior to market open on Monday, December 21, 2015.
... More